CLINICAL_TRIALS
trial_result
· 2024-07-03
Clinical Trial Update: Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis [Phase 3]
Summary
Phase 3 safety-extension trial of inhaled molgramostim for autoimmune pulmonary alveolar proteinosis was terminated; results were posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Savara Inc. | Conditions: Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Status: TERMINATED | Results posted: 2024-07-03